“Our first year shows strong alignment and renewed energy across the organization,” said Associate Dean and Director of ...

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in ...

DMR-001, a potentially best-in-class mutant calreticulin ('mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...

4) Increasing Investor Awareness Through IR Marketing Companies: To enhance liquidity and attract institutional investors, Herbal Dispatch will engage specialized investor relations and marketing ...

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase ...

Healthcare organizations face an increasingly complex digital landscape that is rapidly evolving. How can organizations thrive amid this constant change? New research from Huron identifies five ...

From national sporting events to major community celebrations, 2025 was a milestone year for the Town of Kindersley, with ...

The vision, strategic priorities and theory of change are established at the beginning of the PLAN for Results phase, based on a well-developed situation analysis and planning scenario. This helps ...

Lorigerlimab is a bispecific, tetravalent PD-1 × CTLA-4 DART® molecule designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal ...